How cells start making proteins from uncommon genetic signals
Non-canonical mechanisms of translation initiation and regulation
This work explains how cells sometimes begin making harmful proteins from unusual genetic start signals that can affect people with certain neurological or genetic disorders.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11176813 on NIH RePORTER |
What this research studies
Researchers will study mutated messenger RNAs and the protein-making machinery in cells to see how translation begins at non-standard start signals. They will identify which transfer RNAs can act to start protein synthesis and test how ribosome traffic (queuing) can trigger cell stress and programmed cell death. The team will use molecular experiments in cellular models and analyze human gene mutations linked to disease to map these mechanisms. Results will build a clearer picture of how toxic proteins can arise from changes in how cells begin making proteins.
Who could benefit from this research
Good fit: People with genetic or neurological conditions known or suspected to arise from abnormal protein production, or those with identified mutations that change mRNA start signals, would be most relevant to this work.
Not a fit: People without genetic or neurodegenerative conditions or those seeking immediate clinical treatment are unlikely to benefit directly from this basic science program.
Why it matters
Potential benefit: If successful, this work could reveal new molecular targets to prevent or reduce production of harmful proteins in some genetic and neurodegenerative disorders.
How similar studies have performed: Previous laboratory studies, including work by this team, have shown non-canonical initiation can produce toxic proteins in cell models, but translating those findings toward therapies is still novel.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Kearse, Michael G — Ohio State University
- Study coordinator: Kearse, Michael G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.